Dr. Khan co-chaired the 3rd and 4th International Workshops on Primary Hyperparathyroidism proceedings published in JCEM in 2009 and 2014 respectively . Dr Khan led the development of the international standards of care for hypoparathyroidism published in 2019. Dr. Khan has led the development of medical management options in Primary Hyperparathyroidism including the 1st international study on the use of alendronate in primary hyperparathyroidism as well as the phase 3 trial on the use of cinacalcet in primary hyperparathyroidism. She is currently investigating the use of various PTH molecules in the management of hypoparathyroidism in phase 1, phase 2 and phase 3 clinical trials. She is the principal investigator evaluating the epidemiology, presentation, management and complications of hypoparathyroidism in the Canadian National Hypoparathyroidism Registry.